Horizon Discovery and UCL Institute of Neurology collaborate in rAAV-mediated genome editing
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced it has entered into a research collaboration for gene editing at the Institute of Neurology, University College London (UCL). The programme of research will focus on the creation of human isogenic disease model cell lines with insertion of Huntington’s disease-causing…
Crown Bioscience, Inc. and Horizon Discovery at EORTC-NCI-AACR Symposium
Santa Clara, CA and Cambridge, UK – Crown Bioscience, Inc., a leading global drug discovery and development service company, and Horizon Discovery Ltd., a leading provider of research tools to support the development of personalized medicines, will highlight the availability of X-MAN™ cell lines for in vitro and in vivo drug discovery model validation at the 24th EORTC - NCI - AACR Symposium on…
Leading genome sequencing institute joins Horizon’s Centers of Excellence programme
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, announced it has established a Center of Excellence (CoE) for gene editing with Washington University in St Louis and the BRIGHT Institute. One of the leading genome sequencing facilities in the world, Washington University and the BRIGHT Institute will work with Horizon to translate the…
Horizon Discovery launches SyntheTx Partnership Program to identify novel targets for cancer
H3 Biomedicine is first partner for program aimed at generating ‘first-in-class’ patient-relevant targets based on synthetic lethality screens
Horizon and ATCC sign global licensing and distribution agreement
Cambridge, UK, and Manassas, Virginia- Horizon Discovery Ltd, a leading provider of research tools to support the development of personalized medicines, announced it has signed a licensing and distribution agreement with the American Type Culture Collection (ATCC) for a select set of panels of X-MAN™ isogenic cell lines.
Horizon Discovery and Domainex Ltd collaborate to support lead optimization oncology program
Horizon Discovery Ltd, a leading provider of research tools to support the development of personalised medicines, today announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London.
Horizon Discovery appoints Richard Vellacott as Chief Financial Officer
Horizon Discovery Limited, a leading provider of research tools to support the development of personalised medicines, has announced the appointment of Mr. Richard Vellacott as Chief Financial Officer.
Horizon Discovery collaborates with NIH Center for Regenerative Medicine
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced that it has signed a technology access agreement with the US National Institutes of Health Center for Regenerative Medicine (NIH CRM), through Horizon’s Centers of Excellence (CoE) programme.
Horizon Discovery & University of Leicester co-operate in rAAV-mediated genome editing
Center of Excellence will focus on developing isogenic models of cardiovascular disease
Horizon Discovery and Bayer collaborate to develop cell line models for oncology programmes
Horizon Discovery Ltd, a leading provider of research tools to support the development of personalised medicines, today announced it has signed a collaboration agreement with Bayer Pharma AG (Bayer) to develop preclinical cell line models that will support Bayer’s oncology research and development programmes, using Horizon’s precision genome editing technology, GENESIS™.
Horizon Discovery establishes three new Centres of Excellence
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced it has established three new Centres of Excellence (CoE) for rAAV gene editing, at Dana-Farber Cancer Institute, in Boston, MA, the University of Liverpool, UK and the Babraham Institute, in Cambridge, UK.
Horizon Discovery and H3 Biomedicine collaborate to validate novel cancer targets
H3 Biomedicine to employ Horizon’s unique gene editing technology (GENESIS) and isogenic cell lines (X-MAN) to identify and validate genetically defined drug targets for development of cancer therapeutics.
Horizon Discovery receives Queen’s Award for Enterprise in International Trade
Horizon Discovery receives the Queen’s Award for Enterprise in International Trade - the UK’s most prestigious business award granted in recognition of outstanding achievement in export growth.
Horizon partners with EMQN to minimise variability in cancer diagnostic testing across Europe
Horizon Diagnostics (HDx), a division of Horizon Discovery Limited, a leading provider of research tools to support the development and prescription of personalized medicines, today announced it has signed a strategic partnership agreement with the European Molecular Genetics Quality Network (EMQN).
Horizon and Rosalind Franklin University to develop cystic fibrosis cellular disease models
Horizon Discovery, a leading provider of research tools to support the development and prescription of personalized medicines, announces its collaboration with the Rosalind Franklin University of Medical Sciences (RFUMS) to develop a human cellular disease model of cystic fibrosis.
Horizon Discovery launches rAAV-mediated genome editing support website
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced the launch of rAAVers.org, a site dedicated to supporting scientists around the world working with rAAV-mediated genome editing technology.
Horizon Discovery joins 4D Cell Fate consortium
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced it has joined the EU-FP7 funded ‘4D Cell Fate’ consortium, whose aim is to shed light on how stem cell re-programming and differentiation is regulated at the epigenetic level.
Horizon and UK NEQAS ICC announce partnership to improve accuracy of lung cancer diagnosti...
Horizon’s genetically defined human genomic reference standards are to be used in FISH and IHC proficiency testing to help guide personalised medicine.
Horizon Discovery appoints Eric Rhodes as Chief Technical Officer
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, has announced the appointment of Eric Rhodes as Chief Technical Officer, Gene Targeting.